DE602006020562D1 - Hren dafür - Google Patents

Hren dafür

Info

Publication number
DE602006020562D1
DE602006020562D1 DE602006020562T DE602006020562T DE602006020562D1 DE 602006020562 D1 DE602006020562 D1 DE 602006020562D1 DE 602006020562 T DE602006020562 T DE 602006020562T DE 602006020562 T DE602006020562 T DE 602006020562T DE 602006020562 D1 DE602006020562 D1 DE 602006020562D1
Authority
DE
Germany
Prior art keywords
pegylated
polypeptide
csf
hydroxyl group
amino group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006020562T
Other languages
English (en)
Inventor
Carsten Germansen
Bobby Soni
Grethe Rasmussen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maxygen Inc
Original Assignee
Maxygen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Inc filed Critical Maxygen Inc
Publication of DE602006020562D1 publication Critical patent/DE602006020562D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE602006020562T 2005-06-01 2006-05-26 Hren dafür Active DE602006020562D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68672605P 2005-06-01 2005-06-01
PCT/DK2006/000292 WO2006128460A2 (en) 2005-06-01 2006-05-26 Pegylated g-csf polypeptides and methods of producing same

Publications (1)

Publication Number Publication Date
DE602006020562D1 true DE602006020562D1 (de) 2011-04-21

Family

ID=37308965

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006020562T Active DE602006020562D1 (de) 2005-06-01 2006-05-26 Hren dafür

Country Status (16)

Country Link
US (5) US7381805B2 (de)
EP (1) EP1888119B1 (de)
JP (2) JP5137821B2 (de)
KR (1) KR20080027291A (de)
CN (1) CN101193658B (de)
AT (1) ATE500847T1 (de)
AU (1) AU2006254543A1 (de)
BR (1) BRPI0611221A2 (de)
CA (1) CA2607844C (de)
DE (1) DE602006020562D1 (de)
IL (1) IL187009A0 (de)
MX (1) MX2007015156A (de)
NO (1) NO20075708L (de)
RU (1) RU2007149238A (de)
WO (1) WO2006128460A2 (de)
ZA (1) ZA200709704B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080027291A (ko) 2005-06-01 2008-03-26 맥시겐 홀딩스 엘티디 피이지화된 지-씨에스에프 폴리펩타이드 및 그 제조방법
MX2010002448A (es) 2007-08-27 2010-10-04 Biogenerix Ag Formulacion liquida del g-csf conjugado.
BRPI0918553A2 (pt) * 2008-09-19 2016-03-08 Maxygen Inc método para tratar ou previnir neutropenia em um paciente submetido à exposição à radiação, e, uso de uma variante de fator de estimulação de colônia de granulócito.
US7914828B2 (en) * 2008-10-17 2011-03-29 Levine Brian M Combination herbal product to benefit respiratory tract
TW201138831A (en) * 2009-09-30 2011-11-16 Prolong Pharmaceuticals Inc Modified granulocyte colony stimulating factor (G-CSF)
US20120213728A1 (en) * 2009-10-30 2012-08-23 Merck Granulocyte-colony stimulating factor produced in glycoengineered pichia pastoris
TWI480288B (zh) * 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
WO2012064845A2 (en) * 2010-11-09 2012-05-18 Nektar Therapeutics G-csf polymer conjugates having a releasable linkage
EP2709669A1 (de) 2011-05-17 2014-03-26 Bristol-Myers Squibb Company Verfahren zur aufrechterhaltung der pegylierung von polypeptiden
CN104109199B (zh) * 2013-04-16 2019-04-30 深圳未名新鹏生物医药有限公司 一种聚乙二醇单修饰的人粒细胞集落刺激因子的制备方法及其产品
JP2018519359A (ja) * 2015-06-11 2018-07-19 アンビオ ファーマシューティカルズ，エルエルシー Ｐｅｇ化顆粒球コロニー刺激因子（ｇｃｓｆ）
KR102020995B1 (ko) * 2017-10-30 2019-09-16 한국코러스 주식회사 콜로니자극인자와 폴리올이 접합된 접합물을 고수율로 제조하는 방법
WO2020118136A1 (en) * 2018-12-06 2020-06-11 Board Of Regents, The University Of Texas System Selectively cleavable therapeutic nanoparticles
CN114853872B (zh) * 2022-04-27 2023-11-17 山东新时代药业有限公司 一种聚乙二醇修饰rhG-CSF的制备方法

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US588025A (en) * 1897-08-10 Furnace-door-operating device
WO1985000817A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
JPS61227526A (ja) 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
EP0215126B1 (de) 1985-02-08 1991-07-31 Chugai Seiyaku Kabushiki Kaisha Menschlicher granuloxcyt-kolonie-stimulierungsfaktor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US6004548A (en) 1985-08-23 1999-12-21 Amgen, Inc. Analogs of pluripotent granulocyte colony-stimulating factor
JPS6263335A (ja) 1985-09-13 1987-03-20 Fuji Photo Film Co Ltd 化学反応情報の処理方法
DE3681551D1 (de) 1985-09-30 1991-10-24 Chugai Pharmaceutical Co Ltd Menschlicher granulozyten-colony stimulierender faktor.
DE3771509D1 (de) 1986-01-22 1991-08-29 Chugai Pharmaceutical Co Ltd Pharmazeutischer stoff fuer die foerderung der wiederherstellung der haematopoietischen faehigkeit.
US4908773A (en) 1987-04-06 1990-03-13 Genex Corporation Computer designed stabilized proteins and method for producing same
DK203187A (da) 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
EP0256843A1 (de) 1986-08-11 1988-02-24 Cetus Corporation Expression von G-CSF, Muteine davon und deren Verwendung
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
NO176799C (no) 1986-12-23 1995-05-31 Kyowa Hakko Kogyo Kk DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid
US5714581A (en) 1986-12-23 1998-02-03 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US5214132A (en) 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US5362853A (en) 1986-12-23 1994-11-08 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US4853871A (en) 1987-04-06 1989-08-01 Genex Corporation Computer-based method for designing stablized proteins
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
GB2213821B (en) 1987-12-23 1992-01-02 British Bio Technology Synthetic human granulocyte colony stimulating factor gene
CA1340810C (en) 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
EP0347041A3 (de) 1988-05-13 1990-11-22 Amgen Inc. Zusammensetzungen und Verfahren zur Behandlung oder Verhütung von Infektionen bei Tieren
ES2063783T3 (es) 1988-06-03 1995-01-16 Chugai Pharmaceutical Co Ltd Factor de cristalino humano de estimulacion de colonias de granulocitos y procedimiento para su preparacion.
US5025388A (en) 1988-08-26 1991-06-18 Cramer Richard D Iii Comparative molecular field analysis (CoMFA)
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5104651A (en) 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
US6166183A (en) 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
US20020177688A1 (en) * 1988-12-22 2002-11-28 Kirin-Amgen, Inc., Chemically-modified G-CSF
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5109119A (en) 1989-06-06 1992-04-28 Schering Corporation Crystalline r-h-gm-csf and method
IE66494B1 (en) 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
JPH04502164A (ja) 1989-10-10 1992-04-16 アムジエン・インコーポレーテツド 犬科・猫科動物における感染の治療または予防のための化学組成物及び方法
US5265030A (en) 1990-04-24 1993-11-23 Scripps Clinic And Research Foundation System and method for determining three-dimensional structures of proteins
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
DE4014750A1 (de) 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
US5399345A (en) 1990-05-08 1995-03-21 Boehringer Mannheim, Gmbh Muteins of the granulocyte colony stimulating factor
JP3249147B2 (ja) 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
WO1992004455A1 (en) 1990-08-29 1992-03-19 Genetics Institute, Inc. Multidomain hematopoiesis stimulators
US5124297A (en) 1990-12-07 1992-06-23 Amoco Corporation Olefin polymerization and copolymerization catalyst
DE4105480A1 (de) 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5157736A (en) 1991-04-19 1992-10-20 International Business Machines Corporation Apparatus and method for optical recognition of chemical graphics
EP0586549B1 (de) 1991-05-10 2000-09-20 Genentech, Inc. Auswählen von agonisten und antagonisten von liganden
US5386507A (en) 1991-07-18 1995-01-31 Teig; Steven L. Computer graphics system for selectively modelling molecules and investigating the chemical and physical properties thereof
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
WO1993005169A1 (en) 1991-08-30 1993-03-18 Fred Hutchinson Cancer Research Center Hybrid cytokines
JP2638359B2 (ja) 1991-11-26 1997-08-06 富士通株式会社 分子動力学法の拘束条件作成装置
JPH08507916A (ja) 1992-06-09 1996-08-27 カイロン コーポレイション Ｍ−ｃｓｆの結晶化
ZA933926B (en) 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US6057133A (en) 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
US6153183A (en) 1992-11-24 2000-11-28 G. D. Searle & Company Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production
US5772992A (en) 1992-11-24 1998-06-30 G.D. Searle & Co. Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors
US5738849A (en) 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
JPH08503489A (ja) 1992-11-24 1996-04-16 ジー．ディー．サール アンド カンパニー インターロイキン−３（ｉｌ−３）突然変異ポリペプチド
US5424963A (en) 1992-11-25 1995-06-13 Photon Research Associates, Inc. Molecular dynamics simulation method and apparatus
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
IL112583A0 (en) 1994-02-08 1995-05-26 Amgen Inc Oral delivery of chemically modified proteins
HU217872B (hu) 1994-02-23 2000-04-28 Kyowa Hakko Kogyo Co., Ltd. Polipeptid alkalmazása vérlemezke termelődést elősegítő gyógyszer előállítására
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
AU4658596A (en) 1995-02-03 1996-08-21 G.D. Searle & Co. Novel c-mpl ligands
US6017523A (en) 1995-06-06 2000-01-25 G.D. Searle & Co. Therapeutic methods employing mutant human interleukin-3 (IL-3) polypeptides
AU722759B2 (en) 1995-10-05 2000-08-10 G.D. Searle & Co. Novel C-MPL receptor agonists
BRPI9610977A2 (pt) 1995-10-05 2019-09-17 Searle & Co agonistas receptores hematopoiéticos multi-funcionais
US6100070A (en) 1995-10-05 2000-08-08 G. D. Searle & Co. G-CSF receptor agonists
WO1997012977A1 (en) 1995-10-05 1997-04-10 G.D. Searle & Co. Novel g-csf receptor agonists
US6066318A (en) 1995-10-05 2000-05-23 G.D. Searle & Co. Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
US6660257B1 (en) 1996-10-25 2003-12-09 Pharmacia Corporation Circular permuteins of flt3 ligand
US5969105A (en) 1996-10-25 1999-10-19 Feng; Yiqing Stem cell factor receptor agonists
KR100497423B1 (ko) 1996-10-25 2005-07-07 지.디. 썰 엘엘씨 다기능 키메라 조혈 수용체 아고니스트
WO1998046750A1 (en) 1997-04-11 1998-10-22 G.D. Searle & Co. flt3 LIGAND CHIMERIC PROTEINS
KR100241257B1 (ko) 1997-05-22 2000-02-01 한승수 인체 과립구 콜로니 자극 인자 활성물질 및 그것의 제조방법
CA2263795C (en) 1997-06-06 2008-02-19 Kyowa Hakko Kogyo Co., Ltd. Chemically modified polypeptides
DE69838552T2 (de) 1997-07-14 2008-05-21 Bolder Biotechnology, Inc., Louisville Derivate des wachstumshormons und verwandte proteine
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
AU6246599A (en) 1998-09-25 2000-04-17 G.D. Searle & Co. Method of producing permuteins by scanning permutagenesis
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
EP1141300A1 (de) 1999-01-06 2001-10-10 Xencor, Inc. Nukleic saüre und proteine die, g-csf mutante mit granulopoietischer aktivität sind
KR100689212B1 (ko) 1999-01-29 2007-03-09 암겐 인코포레이티드 Ｇｃｓｆ 결합체
JP2000319298A (ja) 1999-03-04 2000-11-21 Seibutsu Bunshi Kogaku Kenkyusho:Kk 蛋白質複合体の結晶、構造座標、及び構造座標の使用
KR100356140B1 (ko) 1999-07-08 2002-10-19 한미약품공업 주식회사 인간 과립구 콜로니 자극인자 변이체 및 이의 생산 방법
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
AR027509A1 (es) * 2000-01-10 2003-04-02 Maxygen Aps Conjugados g-csf
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
AU2001288220A1 (en) 2000-09-07 2002-03-22 Eli Lilly And Company Hyperglycosylated polypeptides
JP2004524005A (ja) 2000-09-08 2004-08-12 マサチューセッツ　インスティテュート　オブ　テクノロジー Ｇ−ｃｓｆアナログ組成物および方法
GB0022877D0 (en) 2000-09-18 2000-11-01 Isis Innovation Analogues
US20020142964A1 (en) 2000-11-02 2002-10-03 Nissen Torben Lauesgaard Single-chain polypeptides
WO2002036626A1 (en) * 2000-11-02 2002-05-10 Maxygen Aps Single-chain multimeric polypeptides
KR100861810B1 (ko) * 2000-12-11 2008-10-07 코닌클리즈케 필립스 일렉트로닉스 엔.브이. 신호 처리 장치 및 신호 처리 결과 공급 방법
AU2002325819B2 (en) 2001-07-11 2008-06-19 Maxygen, Inc. G-CSF Conjugates
KR20080027291A (ko) 2005-06-01 2008-03-26 맥시겐 홀딩스 엘티디 피이지화된 지-씨에스에프 폴리펩타이드 및 그 제조방법

Also Published As

Publication number Publication date
WO2006128460A2 (en) 2006-12-07
CN101193658A (zh) 2008-06-04
CA2607844C (en) 2012-07-10
US20070009478A1 (en) 2007-01-11
US20080167218A1 (en) 2008-07-10
BRPI0611221A2 (pt) 2010-08-24
RU2007149238A (ru) 2009-07-20
KR20080027291A (ko) 2008-03-26
CA2607844A1 (en) 2006-12-07
JP2008542311A (ja) 2008-11-27
JP2013010765A (ja) 2013-01-17
US7381805B2 (en) 2008-06-03
MX2007015156A (es) 2008-02-15
WO2006128460A3 (en) 2007-03-01
NO20075708L (no) 2008-02-27
US20080090764A1 (en) 2008-04-17
JP5137821B2 (ja) 2013-02-06
IL187009A0 (en) 2008-02-09
EP1888119A2 (de) 2008-02-20
ZA200709704B (en) 2008-11-26
US20070014762A1 (en) 2007-01-18
CN101193658B (zh) 2011-08-31
ATE500847T1 (de) 2011-03-15
AU2006254543A1 (en) 2006-12-07
EP1888119B1 (de) 2011-03-09
US7655766B2 (en) 2010-02-02
US20070014763A1 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
DE602006020562D1 (de) Hren dafür
DK1317537T3 (da) Sammensætninger og fremgangsmåder med G-CSF analoger
HK1205193A1 (en) Recombinant n-glycosylated proteins from procaryotic cells n-
DK1638586T3 (da) Synergistisk sammensætning til behandling af diabetes mellitus
EP1572961A4 (de) Actriib-fusionspolypeptide undverwendungen dafür
EP1778842B8 (de) Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung
IN2015DN02553A (de)
NO20023315D0 (no) G-CSF konjugater
MX2007015958A (es) Composiciones de peptido lkktet y/o lkktnt, y metodos.
MX2009005455A (es) (r)-n-estereoisomeros de analogos de 7,8-saturados-4,5 epoxi-morfinano.
MX2008012748A (es) Un proceso para la concentracion de un polipeptido.
RU2013126581A (ru) Мутанты стрептокиназы и их ковалентно модифицированные формы
WO2006057003A3 (en) Induction of neurogenesis and stem cell therapy in combination with copolymer 1
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
ATE367167T1 (de) Aufbereitung von aldesleukin zur pharmazeutischen verwendung
EP1668030A4 (de) Methode zur verbesserung der wirksamkeit von biologischen antwort-verändernden proteinen und exemplarische muteine
EP1796707A4 (de) Peptide mit spezifischem sitz in herzgefässen und verwandte konjugate und verfahren
ATE554793T1 (de) Konjugat
MX2007014803A (es) Composiciones que penetran el nucleo celular.
NZ514027A (en) Cloning and expression of haemophilus somnus transferrin-binding proteins
WO2004043353A3 (en) Compositions and methods for treating acute myeloid leukemia